OrthoPediatrics Corp. Launches DF2 Brace

OrthoPediatrics Corp. has initiated the limited release of the DF2 Brace. The release is part of the company’s expansion in the non-surgical business for treating pediatric musculoskeletal injuries.
 
The DF2 Brace is intended for femur fracture fixation in pediatric patients aged 6 months to 5 years old instead of spica cast by providing immobilization of the femur, knee, and hip.
 
Spica casts for femur fractures are considered the standard of care and have been used for decades, so the DF2 brace represents a significant advancement in how kids with femur fractures can be treated. This specific brace design has been studied in a multi-center trial and demonstrated equivalent outcomes both radiographically and clinically, and in most cases, eliminated the need to proceed to the operating room where the patient undergoes anesthesia.
 
“This is the first product launch for the OrthoPediatrics Specialty Bracing group and will significantly improve the care of kids with femur fractures,” said Joe Hauser, president of Trauma and Deformity Correction at OrthoPediatrics. “The ability to eliminate anesthesia and complications associated with spica casts, all while reducing the overall cost of care is a significant advancement in pediatric orthopedics for patients, their families and surgeons.”

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing pediatric orthopedics. It has developed a comprehensive product offering to the pediatric orthopedic market, offering 52 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and more than 70 countries outside the United States.